MPNs | Clinical

January 14, 2022

During a Targeted Oncology case-based virtual event, Jamile M. Shammo, MD, discussed testing, risk assessment, and therapy for patients with high-risk myelofibrosis.

January 14, 2022

With rusfertide, clinical trial investigators are poised to fill a clinical gap by addressing iron deficiency in patients with polycythemia vera.

January 11, 2022

Richard T. Silver, MD, discusses which patients with myeloproliferative neoplasms may derive the most benefit from recombinant interferon alpha, based on prior research in the chronic myeloid leukemia space and in patients with myeloproliferative neoplasms.

December 28, 2021

A phase 2 study is underway to determine the efficacy and safety of selinexor in patients with myelofibrosis.

December 14, 2021

Full-dose pacritinib beats ruxolitinib in patients with cytopenic myelofibrosis.

December 14, 2021

Results from the REVEAL study signal link between thrombotic events and white blood cell counts.

November 30, 2021

The FDA has extended the review period of the new drug application for pacritinib as treatment of patients with myelofibrosis and severe thrombocytopenia.

November 25, 2021

Carole Miller, MD, discusses the REVEAL trial design, an observational study on mortality and causes of death in patients with polycythemia vera. 

November 24, 2021

In an interview with Targeted Oncology™, Richard T. Silver, MD, discussed the role of interferon in the treatment of myeloproliferative neoplasm as well as the importance of the 3-year global MPN initiative being conducted by the MPN Research Foundation.

November 22, 2021

The study is currently recruiting in 5 states and aims to determine if ruxolitinib affects GvHD rates in patients received HSCT for the treatment of myelofibrosis.